Special Issue "Advances in Respiratory Allergies"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 1629
2. IRCCS Policlinico San Martino, 16132 Genoa, Italy
Interests: asthma; severe asthma; lung disease; lung physiopathology; T2 inflammation; rhinosinusitis; nasal polyps
In recent decades, increasing knowledge of disease mechanisms has made it possible to address allergic diseases of the respiratory tract more effectively.
An enhanced understanding of type 2 inflammation has led to the use of biologic drugs for the treatment of asthma and rhino-sinus pathologies, which at first only acted on IgE, but now act on interleukin (IL) 5 or its receptor at the IL-4 receptor; in the near future, targeting alarmins with anti-TSLP is expected.
Therapeutic approaches with biologic drugs, in the context of allergic diseases of the respiratory tract, are also associated with allergen-specific immunotherapy, which has long been known to be an important cornerstone in the treatment of the allergic patient.
This Special Issue aims to present a collection of papers detailing both the history of allergy therapy in the respiratory tract field and the most recent innovations in the therapeutic field. Special interest will be paid to biological therapies, action on respiratory allergies, action of drugs on both nasal and bronchial districts, and allergen-specific immunotherapy as a therapy and modifying factor in the natural history of the disease.
Dr. Diego Bagnasco
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- rhino-sinusitis with nasal polyps
- small airways
- new therapies
- personalized and precision medicine